From Name:
From Email:
To Name:
To Email:

Optional Message:

Betrixaban approved as oral VTE preventive

from ASHP

FDA and Portola Pharmaceuticals today announced the approval of betrixaban oral capsules to reduce the risk of venous thromboembolism in adults hospitalized for an acute medical illness who have restricted mobility or other risk factors for thromboembolic complications. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063